Comparative Treatment Outcomes Across Actionable Genomic Alterations in Non-Small Cell Lung Cancer: A Large Multicenter Real-World Study
Authors:
- Yasuhiro KatoYKYasuhiro Kato
- Nobuhiko NishijimaNNNobuhiko Nishijima
- Satoshi TakahashiSTSatoshi Takahashi
- Yukari ShirakuraYSYukari Shirakura
- Miwako OmoriMOMiwako Omori
- Maiko AsaiMAMaiko Asai
- Aya FukuizumiAFAya Fukuizumi
- Kakeru HisakaneKHKakeru Hisakane
- Shinji NakamichiSNShinji Nakamichi
- Susumu TakeuchiSTSusumu Takeuchi
- Akihiko MiyanagaAMAkihiko Miyanaga
- Yoshinobu SaitoYSYoshinobu Saito
Open Access
- 20 May 2026
- journal article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (8)
Abstract
No abstract availableFunding Information
- Japan Society for the Promotion of Science
This publication has 29 references indexed in Scilit:
- Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyJournal of Thoracic Oncology, 2025
- Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillanceLung Cancer, 2025
- A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)Journal of Thoracic Oncology, 2025
- Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)Journal of Thoracic Oncology, 2024
- First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsEuropean Journal of Cancer, 2024
- OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLCJournal of Thoracic Oncology, 2022
- Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialJournal of Thoracic Oncology, 2021
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX StudyJournal of Thoracic Oncology, 2019
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialThe Lancet, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009